Iovance Biotherapeutics, Inc. Stock News

Iovance (IOVA) reports mixed second-quarter results as earnings beat estimates but sales miss the mark.

Oral Presentation of Cohort 3A Data from IOV-COM-202 Phase 2 Clinical Trial of LN-145 in Combination with Pembrolizumab in Anti-PD1-naïve Advanced (metastatic or unresectable) Non-Small Cell Lung Can

Based on feedback from the FDA, Iovance's (IOVA) ongoing mid-stage study on LN-145 in NSCLC could support approval under the accelerated pathway. IOVA also reports encouraging preliminary data.

Iovance is close to launching its first in-house developed therapy. The company recently purchased cancer drug Proleukin from Clinigen Limited.

Iovance Biotherapeutics (NASDAQ: IOVA ) stock is sliding lower on Tuesday after the company announced details of a public share offering. According to a press release, Iovance Biotherapeutics is selli

Futures on the Nasdaq inched higher Tuesday morning. Viridian fell despite announcing some favorable early results from a clinical trial.

WD-40 Co. shares WDFC, +2.08% rallied 4% in premarket trade after the company topped Wall Street estimates for the quarter.

Iovance Biotherapeutics Inc (NASDAQ:IOVA) was last seen up 2.4% at $7.42, after the U.S. Food and Drug Administration (FDA) said a late-stage study of its experimental lung cancer therapy , LN-145 TI

Iovance (IOVA) announces randomizing the first patient in the TILVANCE-301 study evaluating the safety and efficacy of its lifileucel/Keytruda combo therapy in frontline advanced melanoma patients.

SAN CARLOS, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today annou

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?

The FDA set a PDUFA date of Nov. 25 for cell-therapy lifileucel. Iovance focuses on T-cell therapies to treat various cancers.

Iovance Biotherapeutics Inc. NASDAQ: IOVA shares spiked over 20% on its advanced-stage melanoma treatment application to the U.S. Food and Drug Administration (FDA). The company submitted, and the FDA

The shares of Iovance Biotherapeutics Inc   (NASDAQ:IOVA) were last seen up 10.7% to trade at $8.36, after the U.S. Food and Drug Administration (FDA) reportedly accepted the company's license applic

Iovance Biotherapeutics (NASDAQ:IOVA) told investors that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for lifileucel for patients with advanced melan